TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06164730: Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional L

Sponsor: Verve Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 85 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,648,048

Rescue Site Savings

+$1,083,648

Unlock Full NCT06164730 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06164730 Rescue Dossier →